Algert Global’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.83M Buy
+37,930
New +$2.79M 0.03% 728
2025
Q4
– Sell
-35,847
Closed -$1.39M – 1240
2025
Q3
$1.39M Sell
35,847
-196,340
-85% -$6.38M 0.02% 778
2025
Q2
$6.42M Buy
232,187
+1,720
+0.7% +$43.8K 0.13% 249
2025
Q1
$5.12M Buy
230,467
+94,653
+70% +$1.95M 0.13% 265
2024
Q4
$2.69M Buy
135,814
+44,655
+49% +$1.02M 0.06% 506
2024
Q3
$2.28M Buy
91,159
+72,556
+390% +$1.77M 0.06% 511
2024
Q2
$347K Buy
18,603
+8,156
+78% +$153K 0.01% 1059
2024
Q1
$206K Buy
+10,447
New +$204K 0.01% 971
2021
Q2
– Sell
-12,140
Closed -$225K – 479
2021
Q1
$225K Sell
12,140
-22,810
-65% -$467K 0.07% 360
2020
Q4
$618K Hold
34,950
– – 0.18% 188
2020
Q3
$535K Buy
34,950
+4,080
+13% +$76.6K 0.17% 179
2020
Q2
$787K Buy
+30,870
New +$645K 0.27% 137
2019
Q1
– Sell
-10,694
Closed -$300K – 353
2018
Q4
$300K Buy
+10,694
New +$223K 0.08% 280

Other funds holding KNSA

Algert Global's KNSA Position: Q3 2026 in Review

Algert Global opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q3 2026: 37,930 shares worth $2.83M. The stake represents 0.03% of the portfolio and ranks #728 among its holdings. This is a return to the name: Algert Global previously reported a position in KNSA as recently as Q3 2025.

Algert Global first reported a position in KNSA in Q4 2018 and has held it in 13 quarters since. The position peaked at $6.42M in Q2 2025. 305 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • Algert Global held 37,930 shares of Kiniksa Pharmaceuticals worth $2.83M as of Q3 2026.
  • Kiniksa Pharmaceuticals was a new Algert Global position in Q3 2026.
  • Kiniksa Pharmaceuticals made up 0.03% of Algert Global's portfolio in Q3 2026, its #728 holding.
  • Algert Global first reported a position in Kiniksa Pharmaceuticals in Q4 2018 and has held it in 13 quarters since.
  • Algert Global's Kiniksa Pharmaceuticals position peaked at $6.42M in Q2 2025.
  • 305 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Algert Global's 13F filing for Q3 2026, filed 17 Nov 2026.